10-Q: Moleculin Biotech Reports Q1 2025 Results, Highlights Annamycin Clinical Trial Progress

Sentiment:

Quarterly Report 13 May 2025 4:15 PM

Moleculin Biotech's Q1 2025 report details financial results and provides updates on the clinical development of Annamycin, including progress on the Phase 3 MIRACLE trial.

Delay expectedThe Key Opinion Leader (KOL) call announcing and reviewing the final top line data from the MB-107 trial was delayed due to KOL schedules and availability.

Capital raiseThe company states it needs to raise approximately $15 million to support the MIRACLE trial and operations into the first quarter of 2026.The company intends to seek additional funding through a combination of equity offerings, debt financings, government or other third-party funding, commercialization, marketing and distribution arrangements, other collaborations, strategic alliances and licensing arrangements and delay planned cash outlays or a combination thereof.

Worse than expectedThe company's net loss increased from $4.970 million in Q1 2024 to $6.436 million in Q1 2025.

Summary

Moleculin Biotech reported a net loss of $6.436 million for the three months ended March 31, 2025, compared to a net loss of $4.970 million for the same period in 2024.
Research and development expenses decreased to $3.435 million from $4.252 million year-over-year, primarily due to clinical trial activity levels.
General and administrative expenses increased slightly to $2.477 million from $2.393 million year-over-year.
The company recorded a gain from the change in fair value of warrant liability of $9.054 million, compared to $1.455 million in the prior year period.
The company received gross proceeds of $9.3 million in February 2025 from securities offerings.
As of March 31, 2025, Moleculin Biotech had cash and cash equivalents of $7.716 million.
The company believes its current cash is sufficient to fund operations into the third quarter of 2025 and needs to raise approximately $15 million to support the MIRACLE trial and operations into the first quarter of 2026.
The Phase 3 MIRACLE trial for Annamycin is progressing with sites selected in the US, Europe, and the Middle East/Africa.
The European Medicines Agency (EMA) approved the Clinical Trial Application to conduct the MIRACLE trial in nine EU countries.
New preclinical data for Annamycin demonstrating market expansion potential, including treatment for pancreatic cancer, was presented at the American Association for Cancer Research (AACR) Annual Meeting.
The World Health Organization approved 'naxtarubicin' as the International Non-Proprietary Name for Annamycin.
The U.S. Patent and Trademark Office (USPTO) granted two additional U.S. patents with claims covering Annamycin.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While there is progress in clinical trials and regulatory approvals, the increased net loss and the need for additional funding raise concerns. The potential for Annamycin to be a disruptive treatment is a positive factor, but it is still early in the development process.

Positives

The Phase 3 MIRACLE trial is progressing with sites selected in multiple regions.
The EMA approved the MIRACLE trial in nine EU countries.
New preclinical data suggests Annamycin has potential in treating pancreatic cancer.
The company secured $9.3 million in gross proceeds from securities offerings in February 2025.
The company obtained two additional U.S. patents for Annamycin.
The World Health Organization approved 'naxtarubicin' as the International Non-Proprietary Name for Annamycin.

Negatives

The company reported a net loss of $6.436 million for Q1 2025, an increase from the $4.970 million loss in Q1 2024.
The company's cash and cash equivalents stood at $7.716 million as of March 31, 2025.
The company believes its current cash is sufficient to fund operations into the third quarter of 2025.
The company needs to raise approximately $15 million to support the MIRACLE trial and operations into the first quarter of 2026.

Risks

The company's ability to secure additional funding of approximately $15 million is uncertain.
The company is dependent on the success of the MIRACLE trial.
The company is subject to regulatory risks, including potential clinical holds by the FDA.
The company is involved in an SEC investigation, the outcome of which is uncertain.
The company has an accumulated deficit of $159.8 million since inception and has not yet generated any revenues from operations.
The company's auditors may disagree with management's assessment of the company's ability to continue as a going concern.

Future Outlook

The company anticipates needing approximately $15 million to support the MIRACLE trial and operations into the first quarter of 2026 and believes its cash on hand and cash equivalents as of March 31, 2025, is sufficient to fund its planned operations into the third quarter of 2025.

Management Comments

One of our core management beliefs is that anthracyclines represent one of the most important treatments for AML and Advanced STS, and we believe Annamycin may, for the first time ever, allow a majority of these patients to benefit from this treatment.
We believe that such a benefit could be disruptive to the competitive landscape for these markets.
We intend to advance our other drug candidates via investigator led studies both clinically and preclinically.
Although we have not definitively concluded that Annamycin is incapable of cardiotoxicity, we discuss Annamycins lack of demonstrated cardiotoxicity in this document, corporate presentations and other public communications.

Industry Context

The report highlights the competitive landscape for AML and Advanced STS treatments, suggesting Annamycin could be a disruptive force if it proves to be a more effective and less cardiotoxic anthracycline. The company's focus on investigator-led studies for other drug candidates reflects a common strategy for smaller biotech firms to advance their pipeline with limited resources.

Comparison to Industry Standards

The report mentions a retrospective study showing that the incidence of heart failure more than doubles for cancer patients treated with anthracyclines compared to cancer patients not receiving anthracyclines (C Larson, et al. Anthracycline and Heart Failure in Patients Treated for Breast Cancer or Lymphoma, 1985-2010. JAMA Network Open. 2023;6(2):e2254669. doi:10.1001/jamanetworkopen.2022.54669).
This highlights the importance of Annamycin's potential lack of cardiotoxicity compared to other anthracyclines like doxorubicin, daunorubicin, and idarubicin, which are commonly used in AML treatment.
Companies like Celgene (now Bristol Myers Squibb) with Revlimid and Novartis with Rydapt are key players in the AML market, and Annamycin would need to demonstrate superior efficacy and safety to gain significant market share.
In the soft tissue sarcoma market, companies like Eli Lilly with Olaratumab and trabectedin are competitors, and Annamycin would need to show improved outcomes in STS lung metastases to compete effectively.

Legal Proceedings

The company is involved in an SEC investigation related to the development of and statements regarding the company's drug candidate for the treatment of COVID-19.

Related Party Transactions

The Company has two agreements with a related party, Houston Pharmaceuticals, Inc. (HPI) with total expenses o f $59,000 for e ach of the three months ended March 31, 2025 and 2024, respectively.
Accounts payable includes $20,000 as of March 31, 2025 and December 31, 2024, respectively, for related party payables.
The Company recorded approximately $12,000 i n sublease income from a related party for the three months ended March 31, 2025 and 2024.

Stakeholder Impact

Shareholders: The need for additional funding could lead to dilution.
Employees: The company's financial situation could impact job security.
Patients: The progress of Annamycin clinical trials offers hope for a new treatment option.
Creditors: The company's ability to repay debts depends on securing additional funding.

Next Steps

Continue enrollment and data collection for the Phase 3 MIRACLE trial.
Submit results of appropriate nonclinical GLP studies before initiating the Phase 3 portion (Part B) of the MIRACLE study.
Host a Key Opinion Leader (KOL) call to announce and review the final top line data from the MB-107 trial.
Continue preclinical studies with WP1066 IV formula at Emory University.
Seek additional funding to support operations and clinical trials.

Key Dates

Date	Description
April 2, 2012	Date of the Patent and Technology License Agreement between The Board of Regents of the University of Texas System and IntertechBio Corporation, as amended.
December 3, 2021	Date of the Patent And Technology License Agreement between The Board of Regents of The University Of Texas System on behalf of The University Of Texas M. D. Anderson Cancer Center and Moleculin Biotech, Inc.
June 1, 2023	Start date of the 2023/2024 compensation year for executive officers.
December 26, 2023	Date of existing warrants originally issued at an exercise price of $9.60 per share and a termination date of February 14, 2029.
March 22, 2024	The Company completed a reverse stock split of all the issued and outstanding share of the Company's common stock at a ratio of 1 to 15.
August 19, 2024	Closing of public offering of common stock and warrants.
October 2024	Shareholders approved the issuance of the August 2024 warrants, as well as the warrant amendment.
November 4, 2024	The Compensation Committee of the Board of Directors took actions in connection with the executive compensation for the 2023/2024 compensation year.
November 2024	The company amended its existing US investigational new drug application or IND for inclusion of the MIRACLE trial protocol.
February 2025	The company entered into a securities purchase agreement with an institutional investor for the sale by the Company of 1,150,000 shares of common stock, and 2,121,029 pre-funded warrants to purchase shares of common stock, and series D warrants to purchase up to 6,543,058 shares of common stock.
February 2025	The company entered into a warrant exercise inducement offer letter with a holder of certain existing warrants to receive new warrants to purchase up to a number of shares of common stock equal to 200% of the number of warrant shares issued pursuant to the exercise of such existing warrants to purchase up to 5,828,570 shares of common stock.
February 2025	The company received FDA feedback and guidance on that amendment.
February 13, 2025	The Company entered into a warrant exercise inducement offer letter with a holder of certain existing warrants.
February 25, 2025	The Company entered into a securities purchase agreement with an institutional investor for the sale by the Company of 1,150,000 shares of common stock, and 2,121,029 pre-funded warrants to purchase shares of common stock, and series D warrants to purchase up to 6,543,058 shares of common stock.
February 26, 2025	The Company filed a Form 8-K referencing the securities purchase agreement.
March 2025	The Company terminated the WP1122 license with MD Anderson.
March 31, 2025	End of the quarterly period.
April 2025	The Company paid 50% of the executive bonuses and accrued interest from the 2023/2024 compensation year.
April 18, 2025	The company submitted its last response to the FDA.
April 29, 2025	The company announced that new pre-clinical data for Annamycin demonstrating market expansion potential including treatment for pancreatic cancer was presented at the American Association for Cancer Research (AACR) Annual Meeting in Chicago, IL.
April 30, 2025	As of this date, the company has selected 38 sites to conduct the MIRACLE trial in the US, Europe and the Middle East/Africa (MENA).
May 5, 2025	The company announced that the U.S. Patent and Trademark Office (USPTO) granted two additional U.S. patents with claims covering Annamycin.
May 6, 2025	The company announced that the International Nonproprietary Names (INN) Expert Committee of the World Health Organization approved naxtarubicin for the non-proprietary name of the Companys next-generation anthracycline in development, Annamycin.
May 12, 2025	The company announced that the European Medicines Agency (EMA) approved its Clinical Trial Application to conduct its MIRACLE trial in all nine countries submitted in the European Union (EU).
May 13, 2025	Date of the filing of the Quarterly Report on Form 10-Q.
May or early June	Planned Key Opinion Leader (KOL) call announcing and reviewing the final top line data from the MB-107 trial.
End of 2025	Expected interim unblinding of data for the Phase 3 MIRACLE trial.
First half of 2026	Expected additional unblinding of data for the Phase 3 MIRACLE trial.

Keywords

Annamycin, MIRACLE trial, naxtarubicin, AML, Moleculin Biotech, Clinical trial, Warrant liability, Financial results, Biotech, Pharmaceutical

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.